GENEVA– Medimaps Group, a Swiss/Global med-tech company specializing in image processing software for assessing bone health, today announced new appointments to its Board of Directors, effective immediately. Meinhard F. Schmidt, an international MedTech/BioTech and Digital Health executive with 25+ years of experience, has been named Board Chairman; and Anne Le Grand, an accomplished healthcare executive and consultant with 30+ years in the global healthcare technology industry, has joined as an independent board member.
Five additional board members and one board advisor have also been named, bolstering Medimaps investment and clinical policy expertise.
“I’m pleased to welcome Meinhard and Anne to our Board of Directors,” said Prof. Didier Hans, Ph.D., MBA, Chief Executive Officer and Board Member of Medimaps Group. “Meinhard’s global leadership roles in diagnostics at Philips and Roche Diagnostics—and Anne’s work leading medical imaging and healthcare businesses including AI solutions—offer Medimaps significant expertise and acumen to support our immediate growth and shape our future success.”
About the Appointees:
- Mr. Schmidt held senior leadership roles at Philips and Roche Diagnostics where he held various global senior leadership roles in Patient/Diabetes-Care, Laboratory- and PoC-Diagnostics. After that he worked as an executive at Institute Straumann as a Business Unit head and then CEO, where he was responsible for their digital group for the worldwide “Digitalization” of the Dental industry. Currently he holds board and advisory roles for public and private MedTech/Digital Health companies, focusing on growth and commercialization.
- Ms. Le Grand served as global Vice President IBM and General Manager for Watson Health Imaging, Oncology, Genomics and Life Sciences. Prior to IBM, she held executive leadership positions at Philips Health Systems, leading the Therapeutic Care and Ultrasound divisions. Prior to that Ms. Le Grand served as SVP Healthcare of Global X-ray for GE Healthcare, where she successfully launched and refreshed portfolios across the global x-ray, mammography, and metabolic bone disease businesses. She currently holds board and consulting roles for public and private sector healthcare companies.
